Novel therapeutic targets for preserving a healthy endothelium: Strategies for reducing the risk of vascular and cardiovascular disease

Cardiology Journal

Volumn 18, Issue 4, 2011, Pages 355-363

  Ramli, Joseph ^a   Calderonartero, Pedro ^b   Block, Robert C ^b   Mousa, Shaker A ^a,c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Anti coagulant; Anti inflammation; Anti platelet; Cardiovascular disorders; Coronary syndrome; Diagnosis of endothelial function; Endothelial cell; Inflammation; Pro coagulant; Pro platelet; Vascular; Vasoconstriction; Vasodilation

Indexed keywords

2 (4 SALICYLOYL 1 PIPERAZINMETHYL) 3,5,6 TRIMETHYLPYRAZINE; 2 ACYLOXYMETHYL 3,5,6 TRIMETHYLPYRAZINE DERIVATIVE; ADIPONECTIN; ENDOTHELIAL LIPASE; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN; ILOPROST; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; LIPOXIN; NITRIC OXIDE DONOR; ORGANIC NITRATE; PENTAERYTHRITYL TETRANITRATE; PLASMIN; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PYRAZINE DERIVATIVE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; SILENT INFORMATION REGULATOR PROTEIN; SILENT INFORMATION REGULATOR PROTEIN 1; TETRAMETHYLPYRAZINE; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; CARDIOVASCULAR AGENT;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BUERGER DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; CELL PROTECTION; DIET THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; DRUG TOLERABILITY; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE; GENE TARGETING; GRAFT FAILURE; HUMAN; HYPOTENSION; INFLAMMATORY DISEASE; LIMB ISCHEMIA; MECHANICAL STIMULATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REVIEW; RISK REDUCTION; SHEAR STRESS; SIDE EFFECT; SIGNAL TRANSDUCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; TACHYCARDIA; TACHYPHYLAXIS; TARGET CELL; THROMBOMODULIN GENE; THROMBOSIS; THROMBOSIS PREVENTION; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM; VASCULITIS; ANIMAL; DRUG EFFECT; GENE THERAPY; GENETICS; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; GENE THERAPY; HUMANS; TREATMENT OUTCOME;

EID: 79960615758     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics: 2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2009; 119: 480-486.
2. Blann AD. How a damaged blood vessel wall contibutes to thrombosis and hypertension. Pathophysiol Haemost Thromb, 2003; 33: 445-448.
3. Esper RJ, Nordaby RA, Vilarińo JO et al. Endothelial dysfunction: A comprehensive appraisal. Cardiovasc Diabetol, 2006; 5: 4.
4. Steffel J, Luscher TF. Predicting the development of atherosclerosis. Circulation, 2009; 119: 919-921.
5. Thum T, Fraccarollo D, Thum S et al. Differential effects of organic nitrates on endothelial progenitor cells are determined by oxidative stress. Arterioscler Thromb Vasc Biol, 2007; 27: 748-754.
6. Dragoni S, Gori T, Lisi M et al. Pentaerythrityl tetranitrate and nitroglycerin, but not isosorbide mononitrate, prevent endothe-lial dysfunction induced by ischemia and reperfusion. Arterio-scler Thromb Vasc Biol, 2007; 27: 1955-1959.
7. Fayers KE, Cummings MH, Shaw KM, Laight DW. Nitrate tolerance and the links with endothelial dysfunction and oxidative stress. Br J Clin Pharmacol, 2003; 56: 620-628.
8. Daiber A, Wenzel P, Oelze M, Munzel T. New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance. Clin Res Cardiol, 2008; 97: 12-20.
9. Zahler S, Kupatt C, Becker BF. Endothelial preconditioning by transient oxidative stress reduces inflammatory responses of cultured endothelial cells to TNF-alpha. FASEB J, 2000; 14: 555-564.
10. Stokes KY, Dugas TR, Tang Y, Garg H, Giudry E, Bryan NS. Dietary nitrite prevents hypercholesterolemic microvascular inflammation and reverses endothelial dysfunction. Am J Physiol Heart Circ Physiol, 2009; 296: H1281-H1288.
11. Adams TE, Huntington JA. Thrombin-cofactor interactions: Structural insights into regulatory mechanisms. Arterioscler Thromb Vasc Biol, 2006; 26: 1738-1745.
12. Kapur NK, Deming CB, Kapur S. Hemodynamic modulation of endocardial thromboresistance. Circulation, 2007; 115: 67-75.
13. Dittman WA, Majerus P.W. Structure and function of thrombo-modulin: A natural anticoagulant. Blood, 1990; 75: 329-336.
14. Weiler H, Isermann B.H. Thrombomodulin. J Thromb Haemost, 2003; 1: 1515-1524.
15. Van de Wouwer M, Collen D, Conway EM. Thrombomodulin--protein C-EPCR system: Integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol, 2004; 24: 1374-1383.
16. Lin JH, McLean K, Morser J et al. Modulation of glycosami-noglycan addition in naturally expressed and recombinant human thrombomodulin. J Biol Chem, 1994; 269: 25021-25030.
17. Tsiang M, Lentz SR, Sadler JE. Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofac-tor activity. J Biol Chem, 1992; 267: 6164-6170.
18. Mangan S, Clancy P, Golledge J. Modulation of endothelial cell thrombomodulin by PPAR ligands: Variation according to environment. Thromb Res, 2008; 121: 827-834.
19. Tabuchi N, Shichiri M, Shibamiya A et al. Non-viral in vivo throm-bomodulin gene transfer prevents early loss of thromboresistance of grafted veins. Eur J Cardiothorac Surg, 2004; 26: 995-1001.
20. Li J, Garnette CS, Cahn M et al. Recombinant thrombomodulin inhibits arterial smooth muscle cell proliferation induced by thrombin. J Vasc Surg, 2000; 32: 804-813.
21. Ohlin AK, Larsson K, Hansson M. Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma. J Thromb Haemost, 2005; 3: 976-982.
22. Van de Wouwer M, Plaisance S, De Vriese A et al. The lectin--like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost, 2006; 4: 1813-1824.
23. Sajadi S, Ezekowitz MD, Dhond A, Netrebko P. Tissue factor pathway inhibitors as a novel approach to antithrombotic therapy. Drug News Perspect, 2003; 16: 363-369.
24. Kothari H, Kaur G, Sahoo S, Idell S et al. Plasmin enhances cell surface tissue factor activity in mesothelial and endothelial cells. J Thromb Haemost, 2009; 7: 121-131.
25. Undas A, Stepien E, Potaczek DP, Tracz W. Tissue factor +5466A>G polymorphism determines thrombin formation following vascular injury and thrombin-lowering effects of simvas-tatin in patients with ischemic heart disease. Atherosclerosis, 2009; 204: 567-572.
26. Paradis ME, Badellino KO, Rader DJ et al. Endothelial lipase is associated with inflammation in humans. J Lipid Res, 2006; 47: 2808-2813.
27. Ahmed W, Orasanu G, Nehra V et al. High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: A candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion. Circ Res, 2006. 98: 490-498.
28. Gryglewski RJ. Prostacyclin among prostanoids. Pharmacol Rep, 2008; 60: 3-11.
29. Britten MB, Zeiher AM, Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med, 1999; 245: 315-327.
30. Morrow JD, Frei B, Longmire AW et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med, 1995; 332: 1198-1203.
31. di Stefano R, Barsotti MC, Melillo E et al. The prostacyclin analogue iloprost increases circulating endothelial progenitor cells in patients with critical limb ischemia. Thromb Haemost, 2008; 100: 871-877.
32. de Donato G, Gussoni G, de Donato G et al. The ILAILL study: Iloprost as adjuvant to surgery for acute ischemia of lower limbs: A randomized, placebo-controlled, double-blind study by the Italian Society for Vascular and Endovascular Surgery. Ann Surg, 2006; 244: 185-193.
33. He T, Lu T, d'Uscio LV, Lam Ch-f, Lee H-Ch, Katusic ZS. Angiogenic function of prostacyclin biosynthesis in human en-dothelial progenitor cells. Circ Res, 2008; 103: 80-88.
34. Cheng XC, Liu X-Y, Xu W-F, Guo X-L, Ou Y. Design, synthesis, and biological activities of novel ligustrazine derivatives. Bioorg Med Chem, 2007; 15: 3315-3320.
35. Liu X, Zhang R, Xu W et al. Synthesis of the novel ligustrazine derivatives and their protective effect on injured vascular endo-thelial cell damaged by hydrogen peroxide. Bioorg Med Chem Lett, 2003; 13: 2123-2126.
36. Cheng XC, Liu XY, Xu WF et al. Ligustrazine derivatives. Part 3: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents. Bioorg Med Chem, 2009; 17: 3018-3024.
37. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J, 2009; 73: 608-614.
38. Fantuzzi G, Mazzone T. Adipose tissue and atherosclerosis: Exploring the connection. Arterioscler Thromb Vasc Biol, 2007; 27: 996-1003.
39. van Thienen JV, Fledderus JO, Dekker RJ et al. Shear stress sustains atheroprotective endothelial KLF2 expression more potently than statins through mRNA stabilization. Cardiovasc Res, 2006; 72: 231-240.
40. Boon RA, Horrevoets AJ. Key transcriptional regulators of the vasoprotective effects of shear stress. Hamostaseologie, 2009; 29: 39-43.
41. Cunningham KS, Gotlieb AI. The role of shear stress in the pathogenesis of atherosclerosis. Lab Invest, 2005; 85: 9-23.
42. Zarins CK, Giddens DP, Blharadvai BK et al. Carotid bifurcation atherosclerosis. Quantitative correlation of plaque localization with flow velocity profiles and wall shear stress. Circ Res, 1983; 53: 502-514.
43. Potente M, Dimmeler S. Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle, 2008; 7: 2117-2122.
44. Mattagajasingh I, Kim C-S, Naqvi A et al. SIRT1 promotes en-dothelium-dependent vascular relaxation by activating endothe-lial nitric oxide synthase. Proc Natl Acad Sci USA, 2007; 104: 14855-14860.
45. Kim EJ, Um SJ. SIRT1: Roles in aging and cancer. BMB Rep, 2008; 41: 751-756.
46. Serhan CN, Savill J. Resolution of inflammation: The beginning programs the end. Nat Immunol, 2005; 6: 1191-1197.
47. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA, 1995; 92: 9475-9479.
48. Yokomizo T, Izumi T, Shimizu T. Leukotriene B4: Metabolism and signal transduction. Arch Biochem Biophys, 2001; 385: 231 -241.
49. Serhan CN. Resolution phase of inflammation: Novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol, 2007; 25: 101-137.
50. Serhan CN, Arita M, Hong S, Gotlinger K. Resolvins, docosa-trienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids, 2004; 39: 1125-1132.
51. Bannenberg GL, Chiang N, Ariel A et al. Molecular circuits of resolution: Formation and actions of resolvins and protectins. J Immunol, 2005; 174: 4345-4355.
52. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 2005; 352: 1685-1695.
53. Merched AJ, Ko K, Gotlinger KH, Serhan ChN, Chan L. Atherosclerosis: Evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J, 2008; 22: 3595-3606.
54. Tian H, Lu Y, Sherwood AM, Hongqian D, Hong S. Resolvins E1 and D1 in choroid-retinal endothelial cells and leukocytes: Biosynthesis and mechanisms of anti-inflammatory actions. Invest Ophthalmol Vis Sci, 2009; 50: 3613-3620.
55. Dona M, Fredman G, Schwab JM et al. Resolvin E1, an EPA--derived mediator in whole blood selectively counterregulates leukocytes and platelets. Blood, 2008. 112: 848-855.
56. Arita M, Bianchini F, Aliberti J et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med, 2005; 201: 713-722.
57. Arita M, Ohira T, Sun YP et al. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol, 2007; 178: 3912-3917.
58. Kaur J, Adya R, Tan BK et al. Identification of chemerin receptor (ChemR23) in human endothelial cells: Chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun, 2010; 391: 1762-1768.
59. Ohira T, Arita M, Omori K et al. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem, 2010; 285: 3451-3461.
60. Favre J, Gao J, Henry JP et al. Endothelial estrogen receptor {alpha} plays an essential role in the coronary and myocardial protective effects of estradiol in ischemia/reperfusion. Arterio-scler Thromb Vasc Biol, 2010; 30: 2562-2567.